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A B S T R A C T
Background: Emerging acute kidney injury biomarkers, including neutrophil gelatinase-associated
lipocalin (NGAL), have a high potential for predicting worsening renal function. Acute exacerbation of
renal dysfunction has a great impact on the outcomes of cardiovascular patients in critical conditions.
This study aimed to evaluate whether plasma NGAL can predict the mortality and major adverse
cardiovascular events (MACEs) after discharge from the cardiac care unit (CCU).
Methods: Patients who were admitted to the CCU of the Tokyo University Hospital were prospectively enrolled
(101 patients). Blood and urinary markers, including the blood NGAL, brain natriuretic peptide, creatinine,
cystatin C, urinary albumin, N-acetyl-b-D-glucosaminidase, and L-type fatty acid-binding protein, were
measured at CCU discharge. The primary outcome was MACEs until at least 6 months after CCU discharge.
Results: Thirty-ﬁve patients experienced MACEs (35%). Multivariate logistic analysis revealed that the
plasma NGAL, length of CCU stay, and existence of diabetes and heart failure were independent
predicting factors for MACEs. Patients with the highest NGAL at discharge (>75th percentile) showed a
signiﬁcantly higher risk of MACEs than those with the lowest NGAL (<25th percentile) (log-rank test;
hazard ratio, 5.15; 95% conﬁdence interval 1.84–18.20; p < 0.01).
Conclusion: Plasma NGAL at CCU discharge is a signiﬁcant prognostic indicator of outcomes at 6 months
in critically ill cardiac patients treated in a CCU.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Renal dysfunction has been widely recognized as an indepen-
dent exacerbating factor for cardiovascular disease [1,2]. BothAbbreviations: NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute kidney
injury; CCU, cardiac care unit; MACEs, major adverse cardiac events; WRF,
worsening renal function; PCI, percutaneous coronary intervention; L-FABP, L-type
fatty acid-binding protein; KIM-1, kidney injury molecule-1; ADHF, acute
decompensated heart failure; ACS, acute coronary syndrome; NT-proBNP,
N-terminal pro-brain natriuretic peptide; NAG, N-acetyl-b-D-glucosaminidase;
eGFR, estimated glomerular ﬁltration rate; ROC, reciever operating characteristics.
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsacute and chronic renal impairments during the clinical course of
heart diseases, including heart failure and coronary artery disease,
have been deﬁned as cardio-renal syndrome [3]. Critically ill
patients who required cardiac care unit (CCU) admission often
experience acute kidney injury (AKI), which is diagnosed as
worsening renal function (WRF) [4–7]. In these patients, severe
hypotension, decreased cardiac output, and elevated central
venous pressure cause acute renal insults. Furthermore, diagnostic
and therapeutic interventions also cause renal injury; contrast
agents used in percutaneous coronary intervention (PCI) can
induce renal tubular damage, and diuretics used for heart failure
management frequently cause intravascular hypovolemia and
renal hypoperfusion.
To date, new AKI biomarkers, such as neutrophil gelatinase-
associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and
L-type fatty acid-binding protein (L-FABP), have been studied reserved.
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renal tubular cell by renal ischemia or exposure to nephrotoxic
agents, and they are elevated during the acute phase of kidney
injury before the glomerular ﬁltration rate declines. The limita-
tions of serum creatinine for the early detection of renal injury in
AKI are well known [12]; thus, these new biomarkers will allow
clinicians to detect renal injury earlier.
Blood and urine NGAL are emerging biomarkers for AKI. Their
performance in the early detection of renal damage has been
valuable in several AKI cohorts, including post-cardiac surgery AKI
[13]. Recently, several clinical studies found that blood and urine
NGAL can predict WRF, mortality, and major adverse events of
cardiovascular diseases, including acute decompensated heart
failure (ADHF) and acute coronary syndrome (ACS) [14–21]. In
most studies, NGAL was evaluated in ADHF patients, although one
study exclusively targeted a population with ST-elevation myo-
cardial infarction [18]. However, the generalizability and reliability
of new biomarkers should be evaluated in heterogeneous
populations before clinical use. Predictive values of NGAL have
been mostly reported in ADHF patients. However, critically severe
patients treated in CCUs frequently have ACS in addition to ADHF.
Moreover, blood and urine NGAL were usually measured at
admission or before initiating treatment, such as diuretics
administration [20] and PCI [18]. Only one study evaluated the
performance of plasma NGAL measured at discharge [16]; yet,
patients with acute myocardial infarction, active ischemia, and
cardiogenic shock were excluded although these critically ill
conditions are frequently observed in CCUs.
In the present study, we aimed to investigate the clinical use of
plasma NGAL in CCUs, especially for predicting long-term
outcomes. Thus, we evaluated whether plasma NGAL measured
at CCU discharge can predict major adverse cardiac events (MACEs)
at 6-month outcomes. We hypothesized that the measurement of
plasma NGAL at this time point may enable a better risk
stratiﬁcation for long-term outcomes.
Methods
Study design and patient population
The present study consecutively enrolled patients who were
admitted to the CCU of the Tokyo University Hospital (Tokyo,
Japan) from December 2011 to July 2012. Informed consent was
obtained from each participant or the participants’ legal represen-
tative. The study protocol, which adhered to the principles of the
Declaration of Helsinki, was approved by The University of Tokyo’s
Institutional Review Board. Patients were excluded if they had end-
stage renal disease or died during their CCU stay and if there was
any missing data at CCU discharge. Although no clear criteria for
CCU admission exist, severe conditions that require mechanical
circulatory support, pressors, mechanical ventilation or non-
invasive positive pressure ventilation, and emergency cardiac
interventions for ACS were considered for CCU admission based on
the attending physician’s decision.
Data sampling
The following clinical variables were evaluated: age, sex, the
diagnosis for CCU admission, and left ventricular ejection fraction
(LVEF) as measured by transthoracic echocardiogram on admis-
sion day. Two-dimensional imaging examinations were per-
formed in the standard apical four- and two-chamber views.
These images estimated LVEF using the modiﬁed, single-plane
Simpson method. Ischemic heart disease was diagnosed when
coronary artery stenosis was demonstrated by catheter coronary
angiography during the CCU stay. Diagnosis of heart failure wasdetermined according to the Framingham criteria [22]. Treat-
ments during CCU admission included mechanical ventilation,
intravenous inotropic agents, and induction of mechanical
devices such as intra-aortic balloon pump were also recorded.
Attending cardiologists discharged patients from the CCU when
patients were hemodynamically stable and asymptomatic. The
duration of the CCU stay and the entire hospitalization period
were also recorded.
Blood and urine samples were obtained at CCU discharge. The
following biomarkers were measured: plasma NGAL and N-
terminal pro-brain natriuretic peptide (NT-proBNP), serum creati-
nine, cystatin C, BNP, urinary albumin, N-acetyl-b-D-glucosami-
nidase (NAG), and L-FABP. The values of the urinary biomarkers
were normalized to the urinary creatinine concentration. For the
plasma NGAL and NT-proBNP measurements, the Triage NGAL Test
and the Triage NT-proBNP Test (Alere Medical Inc., San Diego, CA,
USA) were used respectively. Other biomarkers were measured as
previously described [23,24]. The estimated glomerular ﬁltration
rate (eGFR) was calculated using the Modiﬁcation of Diet in Renal
Disease equation, which was adjusted for the Japanese population
[25].
WRF was deﬁned as more than a 1.5-fold increase of serum
creatinine from baseline during the hospital stay. The baseline
serum creatinine was deﬁned as the minimum among the
outpatient value within 6 months before admission, the inpatient
value before admission, and the last value before discharge. For a
patient with no creatinine measurement within the past 6 months,
the baseline was deﬁned as the minimum among the last value
before discharge and the estimated value using the Modiﬁcation of
Diet in Renal Disease equation for the lower end of the reference
range (i.e. 75 mL/min/1.73 m2), as the Kidney Disease International
Global Outcomes guideline suggested [26].
Endpoints of the study
The enrolled patients were followed by reviewing their medical
records until at least 6 months after CCU discharge. The follow-up
period in the present study was 248.5  118.9 [258 (178–342)]
days. The primary endpoint was the incidence of a MACE, which
consisted of all-cause mortality, emergent readmission, and coronary
revascularization during the follow-up period. Coronary revasculari-
zation included either elective or emergent PCI or coronary artery
bypass graft during the follow-up period.
Statistical methods
Continuous data are represented as mean  standard deviation
or median (interquartile). Continuous variables were compared using
the Mann–Whitney U test, and categorical variables were compared
using the Pearson x2 or Fisher’s exact test. Step-wise multivariate
logistic regression analysis was conducted to identify the predictors
of MACEs. The following parameters were adopted in the analysis:
biomarkers (plasma NGAL, NT-proBNP, creatinine, eGFR, BNP,
cystatin C, urinary albumin, NAG, and L-FABP) and background or
therapeutic characteristics (history of hypertension, dyslipidemia,
diabetes mellitus, smoking, PCI, and coronary artery bypass grafting,
height, body weight, LVEF, ischemic heart disease, ADHF, mechanical
ventilation use, vasoactive/inotropic agents use, revascularization
during CCU stay, and duration of CCU stay). The receiver operating
characteristics (ROC) curve of each parameter for predicting the
endpoint was drawn, and the cut-off points were determined at
which the Youden index (sensitivity + speciﬁcity  1) was maxi-
mized. The areas under the ROC curve were compared by the method
previously described [27]. The cumulative event-free rate curve of
each group was drawn in the Kaplan–Meier manner and was
compared using the log-rank test or Wilcoxon test.
Table 1
Baseline characteristics of enrolled patients before CCU discharge.
All patients
n = 101
MACE (+)
n = 35
MACE()
n = 66
p-value
Age, years 68.5  12.8 72.9  10.4 66.2  13.4 0.022
Male, % 62 (61%) 21 (60%) 41 (62%) 0.83
Body weight, kg 59.7  14.4 56.9  14.0 61.1  14.4 0.12
Hypertension, % 72 (71%) 28 (80%) 44 (67%) 0.16
Diabetes mellitus, % 30 (30%) 16 (46%) 14 (21%) 0.01
Dyslipidemia, % 61 (60%) 23 (66%) 38 (58%) 0.43
History of PCI, % 18 (18%) 7 (20%) 11 (17%) 0.68
History of CABG, % 3 (3%) 1 (2.9%) 2 (3.0%) 0.96
Smoker, % 54 (53%) 17 (49%) 37 (56%) 0.47
Ejection fraction, % 51.3  16.3 49.8  17.9 52.1  15.3 0.60
Ischemic heart disease
conﬁrmed by CAG, %
52 (51%) 18 (51%) 34 (52%) 0.99
ADHF, % 48 (48%) 24 (69%) 24 (36%) 0.002
Mechanical ventilation, % 12 (12%) 5 (14%) 7 (11%) 0.59
Vasoactive/inotropic
agents, %
24 (24%) 9 (26%) 15 (23%) 0.74
Revascularization
during the CCU stay, %
48 (49%) 13 (37%) 35 (53%) 0.13
CCU stay, d 5 (3.5–9) 6 (4–8) 5 (3–9) 0.38
Whole period of the
hospitalization, d
20 (12–38) 21 (11–38) 20 (12–38.3) 0.97
CCU, cardiac care unit; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass grafting; CAG, coronary artery angiography; ADHF,
acute decompensated heart failure.
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signiﬁcance. These statistical calculations were performed using
the JMP software, version 9.0 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics and outcomes
One hundred and twenty-seven patients were admitted to the
CCU during the study period. Twenty-six patients met the
exclusion criteria; 5 patients died during CCU stay; 8 patients
were on regular hemodialysis at CCU discharge; and 13 were
excluded because of missing data. Finally, 101 patients were
enrolled. The underlying etiologies for CCU admission are shown in
Supplementary Table 1. During the 6-month follow-up period,
35 patients (35%) were classiﬁed as positive for the primary
endpoint of the MACEs. Among those, there were 8 deaths,
20 emergent hospitalizations, and 10 coronary revascularizations
during the follow-up period (Fig. 1). The precise event data are
shown in Supplementary Table 2.
Table 1 shows the patient baseline characteristics before CCU
discharge. Patients who developed MACEs were signiﬁcantly older
and complicated with diabetes more frequently. The prevalence of
ADHF was signiﬁcantly higher in the MACE group than in the non-
MACE group. Although WRF was observed at a similar frequency in
the MACE group and in the non-MACE group (40.0% vs. 30.3%,
p = 0.33), the plasma NGAL values at CCU discharge responded to
WRF with statistical signiﬁcance (Fig. 2). Although WRF occurred
after coronary revascularization in 5 patients, their NGAL levels
were not higher than those of all the patients (Supplementary
Table 3).Fig. 1. Study ﬂow chart. CCU, cardiac care unit; MACE, major adverse cardiac event;
RRT, renal replacement therapy.Association of biomarkers with the MACEs
Fig. 3 represents each blood biomarker measured at CCU
discharge. Only the NGAL and cystatin C were signiﬁcantly higher
in the MACE group than in the non-MACE group. The urinary
biomarkers of albumin, NAG, and L-FABP were not signiﬁcantly
different between these two groups (data not shown). Multivariate
logistic analysis demonstrated that the plasma NGAL, length of
CCU stay, and existing diabetes mellitus and ADHF were
independent risk factors for MACEs after CCU discharge
(Table 2). Among the biomarkers measured at CCU discharge,
the ROC analysis revealed that only the plasma NGAL could predict
MACEs within 6 months after CCU discharge with statistical
signiﬁcance (Table 3).Fig. 2. Comparison of the neutrophil gelatinase-associated lipocalin (NGAL) at
cardiac care unit discharge between patients with or without worsening renal
function (WRF) during hospitalization. The NGAL value was signiﬁcantly higher in
patients with WRF than those without WRF (NGAL: 295.1  281.7 ng/mL vs.
194.6  198.7 ng/mL, respectively; p = 0.014).
Fig. 3. Comparison of the blood biomarkers at cardiac care unit discharge between the major adverse cardiac event (MACE) group and the non-MACE group. The neutrophil
gelatinase-associated lipocalin (NGAL) and cystatin C were signiﬁcantly higher in the MACE group than in the non-MACE group (NGAL: 332.8  327.7 ng/mL vs.
173.1  136.8 ng/mL, respectively, p = 0.005; cystatin C: 1.28  0.64 mg/L vs. 1.08  0.54 mg/L, p = 0.030). NT pro-BNP, N-terminal pro-brain natriuretic peptide; BNP, brain
natriuretic peptide; Cre, creatinine.
Table 2
Multivariate logistic regression analysis for MACE.
Variable b coefﬁcient SE Odds ratio (95% CI)
NGAL (ng/mL) 0.0036 0.0015 1.0036 (1.0008–1.0071)
CCU stay (d) 0.092 0.050 0.91 (0.80–0.98)
DM 0.68 0.27 3.86 (1.36–11.6)
ADHF 0.64 0.26 3.62 (1.32–10.5)
SE, standard error; CI, conﬁdence interval; NGAL, neutrophil gelatinase-
associated lipocalin; CCU, cardiac care unit; DM, diabetes mellitus; ADHF, acute
decompensated heart failure.
Table 3
The receiver operating characteristics analysis for predicting MACE.
Parameter Cut-off AUC 95% CI
NGAL 90.1 ng/mL 0.669 0.541–0.763
NT-pro BNP 5130 pg/mL 0.607 0.463–0.712
Creatinine 1.18 mg/dL 0.590 0.431–0.681
BNP 414.6 pg/mL 0.571 0.427–0.682
Cystatin C 0.87 mg/L 0.634 0.499–0.734
Urinary albumin 47.5 mg/g Cre 0.592 0.441–0.695
Urinary NAG 12.9 U/g Cre 0.554 0.435–0.674
Urinary L-FABP 202 mg/g Cre 0.580 0.412–0.692
NGAL, neutrophil gelatinase-associated lipocalin; NT-pro BNP, N-terminal pro-
brain natriuretic peptide; Cre, creatinine; NAG, N-acetyl-b-D-glucosaminidase;
L-FABP, L-type fatty acid-binding protein; AUC, area under the curve; CI,
conﬁdence interval.
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Fig. 4. The Kaplan–Meier major adverse cardiac event (MACE)-free survival curves according to the neutrophil gelatinase-associated lipocalin (NGAL) value at cardiac care
unit discharge. The patients were divided into three groups by the NGAL value. Red line: patients with >75th percentile (>250 ng/mL, n = 26); blue line: patients with
interquartile (100–250 ng/mL, n = 49); and green line: patients with <25th percentile (<100 ng/mL, n = 26). The hazard ratio of the high NGAL group (>250 ng/mL) to the low
NGAL group (<100 ng/mL) was 5.14 (95% conﬁdential interval 1.84–18.2, p < 0.01). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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To evaluate the association of plasma NGAL with the time-
dependent MACE-free rate, the enrolled patients were classiﬁed
into three groups: the high NGAL (>75th percentile) group, mid
NGAL (interquartile) group, and low NGAL (<25th percentile)
group. Fig. 4 shows the Kaplan–Meier curve analysis of MACE-free
patients divided by the plasma NGAL at CCU discharge. Higher
NGAL levels at discharge were signiﬁcantly associated with a
worse outcome. The Cox proportional hazard model showed that
the hazard ratio of the high NGAL group (>250 ng/mL) to the low
NGAL group (<100 ng/mL) was 5.14 [95% conﬁdence interval (CI)
1.84–18.2, p < 0.01]. For a more effective prediction of the MACEs,
a combination analysis of NGAL and BNP was performed. Firstly,
the area under the curve (AUC) of the ROC curve for the
combination value of the prediction of MACEs was higher than
that of NGAL or BNP alone, but this difference did not reach
statistical signiﬁcance (AUC = 0.675, 95% CI: 0.558–0.774). To
demonstrate the additional effect of BNP, we compared the MACE-
free rate speciﬁed by the combination of NGAL and BNP to that by
NGAL alone (Fig. 5). Patients with a higher value of NGAL and BNPFig. 5. The Kaplan–Meier major adverse cardiac event (MACE)-free survival curves acco
brain natriuretic peptide (BNP) value at cardiac care unit discharge. Red line, patients wit
patients with high NGAL levels only (>90.1 ng/mL, n = 83). Wilcoxon test showed signiﬁ
(For interpretation of the references to color in this ﬁgure legend, the reader is referreabove the cut-off points (NGAL >90.1 ng/mL and BNP >414.6 pg/
mL) had a lower MACE-free rate than those with a high value of
NGAL alone (p = 0.03). Next, we stratiﬁed the patients in four
groups using the cut-off value acquired in the ROC analysis: (1)
high BNP and high NGAL; (2) high BNP and low NGAL; (3) low BNP
and high NGAL; and (4) low BNP and low NGAL. Then the MACE-
free rate was plotted in the Kaplan–Meier manner, and each group
was compared. Fig. 6 shows the cumulative event-free rate curve of
patients divided by the NGAL and BNP levels at CCU discharge.
When the NGAL and BNP were higher than the cut-off values, the
incidence of the MACEs signiﬁcantly increased. The hazard ratio
was 3.05 (95% CI 1.51–5.96, p < 0.01).
Discussion
The present study demonstrated that the plasma NGAL
measured at CCU discharge can predict MACEs in a heterogeneous
cohort of critically ill cardiac patients. In addition, the combination
of NGAL and BNP at CCU discharge provided a distinct prognostic
stratiﬁcation. Our study was clinically relevant for a couple of
reasons. Firstly, it enrolled a wide variety of patients with cardiacrding to the neutrophil gelatinase-associated lipocalin (NGAL) with or without the
h high levels of BNP (>414.6 pg/mL) and NGAL (>90.1 ng/mL, n = 24); and blue line,
cant difference between the curves (95% conﬁdential interval: 1.41–5.54, p < 0.03).
d to the web version of this article.)
Fig. 6. The Kaplan–Meier major adverse cardiac event (MACE)-free survival curves
according to the neutrophil gelatinase-associated lipocalin (NGAL) and brain
natriuretic peptide (BNP) value at cardiac care unit discharge. Red line: patients
with high levels of NGAL and BNP (NGAL >90.1 ng/mL and BNP >414.6 pg/mL,
n = 24); and blue line: other patients (n = 77). When the NGAL and BNP levels were
high, the incidence of the MACEs signiﬁcantly increased. The hazard ratio (HR) was
3.05 (95% conﬁdential interval 1.51–5.96, p < 0.01). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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NGAL was measured at CCU discharge when the patients
responded to the treatment and were in stable conditions.
WRF is one of the strongest risk factors for decompensated
heart failure [28]. The negative impacts by renal injury on the
outcomes of cardiac diseases have been recognized as a part of the
cardio-renal syndrome [3]. Critically ill cardiac patients are
frequently exposed to different potential renal insults such as
contrast media injection, infection, low output, and systemic
congestion. Although WRF is often deﬁned by serum creatinine
elevation, recent development of new AKI biomarkers that can
detect AKI more sensitively than serum creatinine enable clinicians
to monitor renal injury more timely and accurately. Therefore,
several clinical studies evaluated the performance of new AKI
biomarkers in cohorts of cardiac patients. In this study, although
the complication of WRF did not signiﬁcantly differ in patients
with or without MACE, NGAL levels at CCU discharge could not
only predict the MACE but also respond to WRF. Thus, these data
suggested that NGAL levels have better prediction for MACE than
WRF complication.
Chen and colleagues reported the association of AKI biomarkers
measured at CCU admissions with poor clinical outcomes at
6-month follow-up [29]. They demonstrated that urinary NGAL
and serum interleukin (IL)-18 can predict the mortality of CCU
patients, whereas serum cystatin C had the best discriminative
value for predicting AKIs. Alvelos and colleagues reported that the
serum NGAL measured at admission had a signiﬁcant prognostic
predictive value in acute heart failure [21]. Other studies evaluated
the role of NGAL in coronary heart disease patients. For example,
Lindberg and colleagues showed that a high plasma NGAL on
admission independently predicted all-cause mortality and MACEs
within 2 years after primary PCI in ST-segment elevation myocardial
infarction patients [18]. Zografos and colleagues reported that the
NGAL levels were higher in patients with stable coronary heart
disease than in those with normal coronary arteries evaluated by
elective angiography [30].
Only one clinical study examined the performance of NGAL
measured at discharge. Maisel and colleagues reported that the
plasma NGAL at hospital discharge was a strong prognostic
indicator of 30-day outcomes for patients admitted for acute heatfailure [16]. Although the biomarker measurement at CCU
admission is expected to reﬂect the severity of illness and to
predict the short-term outcomes, the measurement at discharge
may provide more clinically relevant signiﬁcance. It appears logical
to assess the NGAL levels at discharge, because the circulatory
dynamics were relatively stable, and many other parameters were
almost uniformly conditioned by hospital discharge. However, the
LVEF data were only measured at CCU admission, because we think
that measuring that at admission reﬂects the severity of acute
injury to the heart better than at any other time point. In addition,
improvement in LVEF may require a longer time than the length of
CCU stay. For these reasons, LVEF was evaluated at admission.
Predicting the long-term outcomes of patients who have recovered
from acute critical conditions can provide additional advantages
for patient management, including close monitoring and intensive
medication. In the present study, we measured biomarkers at
discharge from CCU and found a signiﬁcant association with the
NGAL and poor outcomes after discharge. Therefore, the higher
NGAL group should be closely followed after discharge, and heart
and kidney protective medications, including diuretics, renin-
angiotensin system inhibitors, and inotropic agents, should be
adjusted carefully.
Although the BNP was considered to be standard for the risk
prediction of heart failure [31,32], the measurement of the NGAL
was a powerful predictor for MACEs as well as BNP in patients with
heart failure [16]. Because patients admitted to the CCU have
diverse backgrounds (e.g. ischemic heart disease, cardiomyopathy,
aortic disease, and pulmonary embolism), using a combination of
the NGAL and BNP for risk stratiﬁcation was beneﬁcial in real
clinical practice. While BNP is a marker of ventricular stretch and
therefore a marker of volume overload, NGAL is a marker of renal
tubular injury. Thus, using a combination of these markers may not
only predict cardiac events, but also predict cardio-renal hemody-
namic events in CCU patients. Although BNP did not show any
signiﬁcant association with MACEs in the present cohort, this
biomarker is widely used for evaluating heart failure. A recent
clinical study conducted by Maisel and colleagues reported on a
signiﬁcant predictor of MACEs by using a combination of NGAL and
BNP in a cohort of ADHF (not including ischemic heart disease)
[16]. Similarly, evaluating a combination of NGAL and BNP may
provide clinically relevant information for the predictive value of
MACEs in this cohort.
Why can the AKI biomarker, NGAL, predict the outcomes of
cardiac patients? First, the remote organ is affected by renal injury,
which is recognized as cardio-renal syndrome, and appears to
account for the good outcome prediction by the NGAL in cardiac
patients. Second, several studies suggest the possible role of the
NGAL in heart diseases. Yndestad and colleagues demonstrated the
cardiac NGAL expression by using a rat myocardial infarction
model and human heart failure tissue [33]. The NGAL co-localized
with metalloproteinase-9 and stabilized its protease activity in
infarcted hearts and atherosclerotic plaques, suggesting that the
NGAL causes plaque instability [34]. Thus, the NGAL may have a
strong relation with active vascular remodeling itself and may also
reﬂect the severity of cardiovascular disease, in addition to renal
tubular injury.
Reportedly, the plasma NGAL was increased by sepsis and was
signiﬁcantly higher in septic AKI patients than in other AKI patients
and non-AKI patients [35–37]. These results indicated that the
plasma NGAL reﬂects systemic leukocyte activation. In critically ill
cardiac patients treated in the CCU, systemic inﬂammation caused
by sepsis, pneumonia, device-related infection, and endocarditis
are frequently observed. As previously described, the NGAL has
strong implications in multiple settings of acute critical illness of
AKI, heart failure, coronary heart disease, and systemic inﬂamma-
tion. These wide spectrums, including the extra-renal aspects of
M. Ito et al. / Journal of Cardiology 67 (2016) 184–191190the NGAL, enable it to predict the outcomes of heterogeneous
patients as well.
Study limitations
There are several limitations that may affect the results of our
study. First, it was conducted at a single hospital, and the sample
size (n = 127) was small. Evaluations in multicenter CCUs with
larger cohorts should be conducted to evaluate our ﬁndings
further. Second, we collected only one point of markers. The
comparison of data with that of admission or sequential
measurement of markers will provide more superior insight on
the risk stratiﬁcation. Third, other AKI biomarkers, such as urinary
IL-18 and KIM-1, which were reported to be useful in cardiac
patients [38,39], were not measured in the present study. Fourth,
deﬁnition of MACE included the revascularization and emergent
readmission in this study. Further study with more stringent
endpoints (e.g. only hard-endpoints) is necessary to conﬁrm the
obtained results in this study, although a larger sample size will be
required. Fifth, revascularization rate was high (approximately
20%) in our cohort. The enrolled patients frequently had multi-
vessel disease and were usually complicated with heart failure
because patients with stable angina or pharmacologically con-
trolled unstable angina were not admitted to our CCU. Therefore,
we did not include elective PCI for MACE. We basically treated only
the culprit lesions in these patients, however another revasculari-
zation was often required to prevent the progression of heart
failure in the additional unexpected hospitalization. This unstable
clinical status might explain a high revascularization rate in this
cohort. Finally, although baseline serum creatinine should impact
the diagnosis of WRF and AKI by deﬁnition, no standardized
criteria have been suggested to date. Recent clinical studies
evaluated the impact of different deﬁnitions of baseline serum
creatinine on the AKI diagnosis and severity [40,41]. In addition,
the serum creatinine at CCU admission and discharge seemed to
not be proper baseline values. Some patients showed increased
serum creatinine concentrations at CCU admission, while others
had a persistent elevation in the serum creatinine concentrations
until CCU discharge compared to the outpatient measurements.
Therefore, we deﬁned the baseline serum creatinine as the
minimal value for each patient.
In conclusion, our study demonstrated that the plasma NGAL at
discharge can be a signiﬁcant predictor for prognosis among
patients in the CCU. Furthermore, a combination of the NGAL and
BNP provides a remarkably accurate prediction of adverse events.
The measurement of the NGAL at discharge may enable us to
identify the high-risk patients and to adjust the management of the
patients. Further study is expected to conﬁrm the predictive power
of the NGAL in cardiovascular diseases.
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